Screening the Mechanism of Shikonin Against Renal Cell Carcinoma via Network Pharmacology, Molecular Docking, and Cellular Experimental Verification

Population: Renal Cell Carcinoma. Intervention: split-GAL4 lines.

View Full Paper

Ask AI

Bookmark

Share

Key Points

Investigate the mechanisms by which shikonin affects renal cell carcinoma using various analytical approaches.
Utilized network pharmacology to identify potential interactions of shikonin.
Conducted molecular docking studies to assess binding affinities with targets.
Performed cellular experiments to validate the findings of the in silico analyses.
Shikonin demonstrated significant inhibitory effects on renal cell carcinoma cells in vitro.
Molecular docking revealed high affinity interactions with multiple cancer-related targets.
Network pharmacology identified key pathways involved in the anticancer activity of shikonin.

P

Population

Renal Cell Carcinoma

I

Intervention / Comparator

split-GAL4 lines

Examines shikonin's mechanism against renal cell carcinoma, suggesting novel therapeutic pathways.

No takes yet. Share an insight, caveat, or question.

Gong et al. (2026) studied Renal Cell Carcinoma. split-GAL4 lines was evaluated.